144 related articles for article (PubMed ID: 29290997)
1. Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.
Dilly AK; Honick BD; Lee YJ; Guo ZS; Zeh HJ; Bartlett DL; Choudry HA
Oncotarget; 2017 Dec; 8(63):106888-106900. PubMed ID: 29290997
[TBL] [Abstract][Full Text] [Related]
2. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
3. Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.
Dilly AK; Lee YJ; Zeh HJ; Guo ZS; Bartlett DL; Choudry HA
Transl Res; 2016 Mar; 169():19-30.e1. PubMed ID: 26589109
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
[TBL] [Abstract][Full Text] [Related]
5. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
6. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
7. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Dilly A; Honick BD; Lee YJ; Bartlett DL; Choudry HA
Cancer Med; 2020 Mar; 9(5):1753-1767. PubMed ID: 31958897
[TBL] [Abstract][Full Text] [Related]
8. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.
Szych C; Staebler A; Connolly DC; Wu R; Cho KR; Ronnett BM
Am J Pathol; 1999 Jun; 154(6):1849-55. PubMed ID: 10362811
[TBL] [Abstract][Full Text] [Related]
10. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.
Saarinen L; Nummela P; Leinonen H; Heiskanen A; Thiel A; Haglund C; Lepistö A; Satomaa T; Hautaniemi S; Ristimäki A
Mol Cell Proteomics; 2018 Nov; 17(11):2107-2118. PubMed ID: 30072579
[TBL] [Abstract][Full Text] [Related]
11. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
12. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study.
Mall AS; Lotz Z; Tyler M; Goldberg P; Rodrigues J; Kahn D; Chirwa N; Govender D
Case Rep Gastroenterol; 2011 Jan; 5(1):5-16. PubMed ID: 22347149
[TBL] [Abstract][Full Text] [Related]
14. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
Smeenk RM; van Velthuysen ML; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2008 Feb; 34(2):196-201. PubMed ID: 17524597
[TBL] [Abstract][Full Text] [Related]
15. Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms.
Chang MS; Byeon SJ; Yoon SO; Kim BH; Lee HS; Kang GH; Kim WH; Park KJ
Pathobiology; 2012; 79(1):45-53. PubMed ID: 22236547
[TBL] [Abstract][Full Text] [Related]
16. Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix.
Honoré C; Caruso F; Dartigues P; Benhaim L; Chirica M; Goéré D; Elias D
Anticancer Res; 2015 Sep; 35(9):4943-7. PubMed ID: 26254392
[TBL] [Abstract][Full Text] [Related]
17. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
18. The Biological Synthesis and the Function of Mucin 2 in Pseudomyxoma Peritonei.
Lin YL; Li Y
Cancer Manag Res; 2021; 13():7909-7917. PubMed ID: 34703312
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.
Hokari R; Lee H; Crawley SC; Yang SC; Gum JR; Miura S; Kim YS
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G949-59. PubMed ID: 16227528
[TBL] [Abstract][Full Text] [Related]
20. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.
Saarinen L; Nummela P; Thiel A; Lehtonen R; Järvinen P; Järvinen H; Aaltonen LA; Lepistö A; Hautaniemi S; Ristimäki A
PLoS One; 2017; 12(4):e0174898. PubMed ID: 28426742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
